Based on the data from the ELIANA (ALL) [1] and JULIET (diffuse large B cell lymphoma (DLBCL)) [10] as well as ZUMA-1 (DLBCL and primary mediastinal B-cell lymphoma (PMBCL)) [9,11] trials, two second-generation CD19-directed CART products, i.e., axicabtagene ciloleucel (axi-cel, Yescarta; CD28 costimulatory domain) and tisagenelecleucel (tisa-cel, Kymriah; 4-1BB costimulatory domain), have been approved. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.